Back to Authors

Master, Zubin

0000-0002-3462-4546

Mayo Clinic

Associate Professor, Biomedical Ethics Research Program & Center for Regenerative Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA.

Citations 17

Evaluating the FDA Regenerative Medicine Framework: Opportunities for Stakeholders

Regenerative Medicine | August 20, 2020 | Volume: 15 | Issue: 7 | Pages: 1825-1832

10.2217/rme-2020-0073 | PMID 32815780

Challenging Misinformation and Engaging Patients: Characterizing a Regenerative Medicine Consult Service

Regenerative Medicine | April 22, 2020 | Volume: 15 | Issue: 3 | Pages: 1427-1440

10.2217/rme-2020-0018 | PMID 32319855

Survey of equal contributions in biomedical research publications

Accountability in Research | January 27, 2020 | Volume: 27 | Issue: 3 | Pages: 115-137

10.1080/08989621.2020.1722947 | PMID 31986059

Fostering a prevention mindset for responsible gene editing

Accountability in Research | May 10, 2019 | Volume: 26 | Issue: 4 | Pages: 251-256

10.1080/08989621.2019.1617140 | PMID 31074637

Preparing Regenerative Therapies for Clinical Application: Proposals for Responsible Translation

Regenerative Medicine | January 17, 2019 | Volume: 14 | Issue: 2 | Pages: 77-84

10.2217/rme-2018-0163 | PMID 30651044

The stem cell market and policy options: a call for clarity

Journal of Law and the Biosciences | October 15, 2018 | Volume: 5 | Issue: 3 | Pages: 743-758

10.1093/jlb/lsy025 | PMID 31143461

Industry Responsibilities in Tackling Direct‐to‐Consumer Marketing of Unproven Stem Cell Treatments

Clinical Pharmacology & Therapeutics | July 11, 2017 | Volume: 102 | Issue: 2 | Pages: 177-179

10.1002/cpt.704 | PMID 28695633

The direct‐to‐consumer marketing of unproven stem cell interventions (SCIs) is a serious public health concern. Regulations and education have had modest impact, indicating that different actors must play a role to stop this unfettered market. We consider the role of the biotech industry in tackling unproven SCIs. Grounded in the concept of corporate social responsibility, we argue that biotech companies should screen consumers to ensure that products and services are being used appropriately and educate employees about unproven SCIs.